Growth hormone deficiency (GHD) specialists Sara DiVall, MD, and Kevin Yuen, MD, explore ways to optimize outcomes in the diagnosis and treatment of GHD in children, including considerations for the use of long-acting growth hormone (LAGH) products. Topics include the epidemiology, clinical manifestations, and burden of GHD in children and adolescents, evidence-based diagnosis of GHD, guidelines and recommendations for treatment, integrating shared decision-making with patients and/or their parents to develop and modify the treatment plan, and clinical trial data regarding daily and new and emerging LAGH products. Case studies based on common clinical scenarios are discussed to examine how to apply this information in clinical practice to optimize long-term self-management.
Editor's Note: The faculty for this activity has disclosed that there is discussion about the use of products for non-FDA approved applications.
Course Credit:
1.50 AMA PRA Category 1 CreditsTM
1.50 ANCC Contact Hours
Dates:
Opens: 2022-03-18
Closes: 2023-03-18
Target Audience:
This activity was developed for pediatric endocrinologists, pediatricians, nurse practitioners, physician assistants and other healthcare providers who treat children and adolescents with growth and growth hormone disorders.
This activity is supported by an educational grant from Novo Nordisk Inc.
-
Sara DiVall, MD
Associate Professor of Pediatrics
Fellowship Director
Seattle Children’s Hospital
Seattle, Washington -
Kevin Yuen, MD
Medical Director
Barrow Pituitary Center
Barrow Neuroendocrine Clinic
Phoenix, Arizona
